Wearables help manage neurological disorders, predict symptoms
New, wearable technology not only helps monitor symptoms automatically, it may be able to predict seizures and disease progression in patients with neurological disorders.
FDA approved first 3D printed drug. What are other applications for this technology?
The FDA just approved the first 3D printed drug. Are there other applications for this technology?
presented by
These Are the Top-Rated Autism Therapy Centers in Texas
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
Morning Read: FDA approves the first 3D printed drug, OraSure Ebola test gets FDA Emergency Use Authorization
The FDA has approved a 3D-printed drug designed to treat epileptics, OraSure Technologies' Ebola test gets emergency use authorization.
Implantable brain device could restore lost memories, help create new ones
Here’s a story with a slight Cyborg ring to it: An implantable brain device that can potentially restore the memory of patients with traumatic brain injury, Alzheimer’s disease, epilepsy and related conditions is being developed at the government’s Lawrence Livermore National Laboratory. The technology sits at the nexus of human, neuron-based memory and digital, computer chip-based memory: The device […]
Parents launch an Indiegogo campaign for a night-time seizure monitor
It’s easier to help a person having an epileptic seizure in the well-lit daytime as opposed to the pitch-black night. That’s the problem the SAMi monitor is changing. SAMi founders Cynthia and Charles Anderson created the device to help monitor the seizures their son was having at night. Charles, who is an engineer, developed the […]
Elite 8: Wearable startups tracking cancer, seizures, heart trouble, babies
We just talked about how to move digital health beyond the healthiest people in the room. Many of the wearable companies who have survived to this round of the Wearables Sweet 16 are doing just that. Instead of tracking steps taken or floors climbed, these companies are aiming to diagnose breast cancer sooner, increase access […]
presented by
The Top Appointment Scheduling Software for Wellness Clinics
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
A smart watch for epilepsy patients issues mobile alerts when it detects irregular shaking
This smart watch doesn’t track steps or heart rate or sleep patterns. And it’s not something you’d necessarily want to wear. But it’s helping people with epilepsy, their families and their caretakers have some peace of mind. The watch contains a GPS module and a sensor so that it continuously monitors someone for abnormal shaking […]
Global market for neuromodulation devices to grow to $6.8 billion by 2017
A new market report from MarketsandMarkets, a Dallas-based market research firm, is projecting that the global market for neuromodulation devices is set to grow to $6.8 billion by 2017. Another report from October estimated that this same market will increase to $7.07 billion in 2018. Neuromodulation devices, whether implanted or external, treat certain diseases by […]
ACOR’s Neuronex acquisition worth up to $133M; hinges on epilepsy drug
Central nervous system therapies company Neuronex is being acquired by Acorda Therapeutics (NASDAQ:ACOR) in a deal valued at up to $133 million, yielding to Acorda a novel epilepsy treatment nearly ready for filing with the U.S. Food and Drug Administration. But privately held Neuronex gets just $2 million up front. Critical to the Morrisville, North […]
New drugs for epilepsy, pain are focus of NeuroTherapeutics’ $47.5M round
A Chicago biopharmaceutical company developing new ways to treat pain, epilepsy and other nervous system disorders is following up a $43 million series B round of funding in 2010 with another round of up to $47.5 million. NeuroTherapeutics Pharma Inc. is developing a new class of medicines for neurological and neuropsychiatric conditions that includes its […]
presented by
Immune Support on Demand: Ranking the Top Mobile IV Therapy Companies
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Duke University gets $25M grant to research genetics of epilepsy
Duke University Medical Center has been awarded a $25 million federal grant to research epilepsy in an effort to understand its genetic roots and develop new treatments for the disorder. The National Institute of Neurological Diseases and Stroke, a part of the National Institutes of Health, funded the grant as part of its “Center Without […]
Pfizer acquires Icagen for $56 million
Pfizer (NYSE:PFE) will acquire North Carolina drug development company Icagen (NASDAQ:ICGN) for $56 million in a move to bolster its own pain drug pipeline. Under terms of the agreement, Pfizer, which already owns about 11 percent of Research Triangle Park-based Icagen’s stock, will acquire the remaining 8.3 million Icagen stock for $6 per share. Pfizer […]
Pfizer-Icagen merger: What ICGN could bring to PFE’s portfolio
Pfizer (NYSE:PFE) is now talking about a possible acquisition of Icagen (NASDAQ:ICGN). But, already, Pfizer is Icagen’s primary supporter. Icagen, which is based in Durham, North Carolina, has relied on a 2007 partnership with Pfizer to develop drug candidates to treat pain. Icagen’s compounds modulate ion channels, which are protein structures found in the cells […]
GSK epilepsy drug approved by FDA; classified as a controlled substance
GlaxoSmithKline (NYSE:GSK) and drug partner Valeant Pharmaceuticals (NYSE:VRX) have received U.S. Food and Drug Administration approval on a new epilepsy drug, but it must be classified as a controlled substance and regulators are also requiring a formal strategy to inform doctors and patients about the drug’s risks. Ezogabine, which will be marketed in the United […]
UCB’s off-label marketing of epilepsy drug Keppra costs $34M fine (Morning Read)
Current medical news from today, including: UCB reaches settlement over off-label marketing of its epilepsy drug Keppra; the Food and Drug Administration warns of higher prostate cancer risks from baldness and prostate drugs; flu shots reach an all time high; and UCLA partners with Roche for stem cell and cancer research.